Abstract
Deubiquitinase (DUB) is an essential component in the ubiquitin—proteasome system (UPS) by removing ubiquitin chains from substrates, thus modulating the expression, activity, and localization of many proteins that contribute to tumor development and progression. DUBs have emerged as promising prognostic indicators and drug targets. DUBs have shown significant roles in regulating breast cancer growth, metastasis, resistance to current therapies, and several canonical oncogenic signaling pathways. In addition, specific DUB inhibitors have been identified and are expected to benefit breast cancer patients in the future. Here, we review current knowledge about the effects and molecular mechanisms of DUBs in breast cancer, providing novel insight into treatments of breast cancer-targeting DUBs.
Highlights
The ubiquitin–proteasome system (UPS) is one of the protein degradation pathways in eukaryotic cells
We summarize the past five years of results, and go a step further by discussing how DUBs function in every stage of breast cancer progression, including tumor growth, tumor metastasis, immunosuppression, chemoresistance, Life 2021, 11, 965
PHF8 is stabilized by USP7 through deubiquitination, resulting in increased expression of cyclin A2, which promotes the proliferation of breast cancer cells and accelerates tumor growth
Summary
The ubiquitin–proteasome system (UPS) is one of the protein degradation pathways in eukaryotic cells. We summarize the past five years of results, and go a step further by discussing how DUBs function in every stage of breast cancer progression, including tumor growth, tumor metastasis, immunosuppression, chemoresistance, Life 2021, 11, 965. Life 2021, 11, x cancer progression, including tumor growth, tumor metastasis, immunosuppression, and radioresistance breast cancer. The therapeutic forpotential the pharmacological chemoresistance, and in radioresistance in breast cancer. Thepotential therapeutic for the cancer progression, including tumor growth,is tumor metastasis, immunosuppression, modulation of DUB activities is discussed. The therapeutic potential for the pharmacological modulation of DUB activities is discussed. Ubiquitin (Ub) is activated by E1 in is one of the protein degradation pathways in eukaryotic cells. Ubiquitin (Ub) is activated by E1 in an ATP-dependent manner and thendegradation transferred to
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
